Physicians often fail to achieve recommended low-density lipoprotein (LDL) cholesterol
goals for their patients using lipid-lowering therapies in the primary care setting. A variety of …

Introduction: Rosuvastatin is a highly efficacious statin approved for use throughout the
world. Rosuvastatin has been exhaustively evaluated in the setting of a broad variety of …

Background Rosuvastatin is a lipid-lowering drug that works by inhibiting 3-hydroxy-3-
methylglutaryl coenzyme A reductase, the rate-limiting enzyme responsible for producing …

Patients with elevated low-density lipoprotein (LDL) cholesteral levels are at high risk of
cardiovascular events but are often undertreated and fail to achieve lipid goals. This open …

Study Objective. To compare, in a usual care setting, the effects of rosuvastatin and other 3‐
hydroxy‐3‐methylglutaryl coenzyme A inhibitors (statins) on lipid levels and on goal …

Background: Rosuvastatin is a fully synthetic statin developed by AstraZeneca. It is a
competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase. Objective: We reviewed …

SUMMARY In the Statin Therapies for Elevated Lipid Levels compared Across doses to
Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared …

Background: The HMG Co-A reductase inhibitors (statins) are the most efficacious agents for
lowering cholesterol. Statins reduce clinical cardiovascular events and are generally well …

Purpose The purpose of this study was to compare incidence rates of hospitalization
associated with rhabdomyolysis, myopathy, renal, or hepatic dysfunction, and of in‐hospital …